Anixa Biosciences Inc (ANIX) - Total Assets
Based on the latest financial reports, Anixa Biosciences Inc (ANIX) holds total assets worth $14.87 Million USD as of April 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Anixa Biosciences Inc - Total Assets Trend (1985–2025)
This chart illustrates how Anixa Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Also see Anixa Biosciences Inc (ANIX) total market value for the company's overall valuation and market capitalisation.
Anixa Biosciences Inc - Asset Composition Analysis
Current Asset Composition (October 2025)
Anixa Biosciences Inc's total assets of $14.87 Million consist of 98.8% current assets and 1.2% non-current assets. Review Anixa Biosciences Inc (ANIX) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1985–2025)
This chart illustrates how Anixa Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ANIX live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anixa Biosciences Inc's current assets represent 98.8% of total assets in 2025, an increase from 90.9% in 1985.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2025, down from 84.9% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1985.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Anixa Biosciences Inc Competitors by Total Assets
Key competitors of Anixa Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Anixa Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.79 | 8.89 | 30.67 |
| Quick Ratio | 9.79 | 8.89 | 30.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $13.19 Million | $14.88 Million | $35.84 Million |
Anixa Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Anixa Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.64 |
| Latest Market Cap to Assets Ratio | 5.50 |
| Asset Growth Rate (YoY) | -25.5% |
| Total Assets | $16.08 Million |
| Market Capitalization | $88.46 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Anixa Biosciences Inc's assets at a significant premium (5.50x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Anixa Biosciences Inc's assets decreased by 25.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Anixa Biosciences Inc (1985–2025)
The table below shows the annual total assets of Anixa Biosciences Inc from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-10-31 | $16.08 Million | -25.52% |
| 2024-10-31 | $21.59 Million | -15.40% |
| 2023-10-31 | $25.52 Million | -16.08% |
| 2022-10-31 | $30.41 Million | -16.12% |
| 2021-10-31 | $36.26 Million | +283.56% |
| 2020-10-31 | $9.45 Million | +50.20% |
| 2019-10-31 | $6.29 Million | -2.40% |
| 2018-10-31 | $6.45 Million | -26.82% |
| 2017-10-31 | $8.81 Million | +56.58% |
| 2016-10-31 | $5.63 Million | -39.71% |
| 2015-10-31 | $9.34 Million | +3.09% |
| 2014-10-31 | $9.06 Million | +66.47% |
| 2013-10-31 | $5.44 Million | -3.91% |
| 2012-10-31 | $5.66 Million | -34.53% |
| 2011-10-31 | $8.65 Million | -13.94% |
| 2010-10-31 | $10.05 Million | +2.01% |
| 2009-10-31 | $9.85 Million | +31.35% |
| 2008-10-31 | $7.50 Million | +300.92% |
| 2007-10-31 | $1.87 Million | +0.35% |
| 2006-10-31 | $1.86 Million | +27.10% |
| 2005-10-31 | $1.47 Million | -36.69% |
| 2004-10-31 | $2.32 Million | -0.62% |
| 2003-10-31 | $2.33 Million | -14.68% |
| 2002-10-31 | $2.73 Million | -58.38% |
| 2001-10-31 | $6.56 Million | -4.82% |
| 2000-10-31 | $6.89 Million | -14.88% |
| 1999-10-31 | $8.10 Million | -39.10% |
| 1998-10-31 | $13.30 Million | -33.50% |
| 1997-10-31 | $20.00 Million | -19.03% |
| 1996-10-31 | $24.70 Million | +154.64% |
| 1995-10-31 | $9.70 Million | +46.97% |
| 1994-10-31 | $6.60 Million | -24.14% |
| 1993-10-31 | $8.70 Million | +97.73% |
| 1992-10-31 | $4.40 Million | +2.33% |
| 1991-10-31 | $4.30 Million | +2.38% |
| 1990-10-31 | $4.20 Million | 0.00% |
| 1989-10-31 | $4.20 Million | +100.00% |
| 1988-10-31 | $2.10 Million | +75.00% |
| 1987-10-31 | $1.20 Million | -20.00% |
| 1986-10-31 | $1.50 Million | -54.55% |
| 1985-10-31 | $3.30 Million | -- |
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged … Read more